Navigation Links
Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
Date:8/14/2013

man patients, as well as to assess the safety and preliminary efficacy of the Neo-Urinary Conduit.

Neo-Kidney Augment Program Update
The Neo-Kidney Augment is Tengion's second clinical program and is being developed with the goal of using a patient's own kidney cells to augment or replace renal function for patients with chronic kidney disease (CKD) who are rapidly progressing toward end stage renal disease (ESRD). The Neo-Kidney Augment is intended to prevent or delay the need for dialysis or kidney transplant by catalyzing the regeneration of functional kidney tissue in patients with ESRD.

In April 2013, Tengion announced the acceptance of the Company's Clinical Trial Application filed with the Medical Products Agency in Sweden to initiate a Phase 1 clinical trial to evaluate the safety and delivery of the Neo-Kidney Augment, in patients with CKD. The Company plans to enroll up to five patients in the Phase 1 trial in 2013 and will follow each patient for up to two years. The trial will involve delivery of an active regenerative dose of Neo-Kidney Augment in patients with CKD. The Company plans to initiate a Phase 1 trial in the U.S. during the fourth quarter of 2013 to evaluate the Company's Neo-Kidney Augment in patients with CKD.

Recent Corporate Highlights
In June 2013, Tengion closed transactions totaling $33.6 million, including a strategic investment from Celgene Corporation in the form of a $15 million payment in cash. Celgene was granted right of first negotiation on the Neo-Kidney Augment program and also the exclusive option to acquire the assets required for development of a neo-esophageal implant. Celgene also received warrants to purchase shares of Tengion common stock. Additionally, the Company completed a private placement of $18.6 million aggregate principal amount of Senior Secured Convertible Notes and warrants to both new and existing investors.

Second Quarter Financial Update
For the second quarter ended
'/>"/>

SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Tengion Reports Second Quarter 2012 Financial Results
2. Tengion to Present at the BIO CEO & Investor Conference
3. Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
4. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
6. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
7. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
8. Elevate Provides Remote Access to Personal Health Records Using MyMedicalRecords.com
9. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
10. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
11. Concord Medical Announces its Successful Closing of the Acquisition of 52% Ownership in Changan Hospital and Provides Guidance for Financial Results of the Second Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... De Pfizer Clinical Research Unit (PCRU) heeft ... van Japanse komaf voor medewerking aan klinisch onderzoek. De ... één van twee onderzoekseenheden van Pfizer , een ... door de ontdekking en ontwikkeling van nieuwe medicijnen. Om ... mannen en vrouwen van Japanse komaf – leeftijd 18 ...
(Date:7/30/2014)... , July 30, 2014  Cepheid (Nasdaq: ... group purchasing contract with Premier will end on ... Premier GPO will be able to continue their ... Baycare, HPA, MedAssets, Novation, and ROi, in addition ... directly with Cepheid. "Cepheid has always ...
(Date:7/30/2014)... 2014 The Board of Directors of ... evening expressed support for the "Pharmacists, Patient Care ... Pharmacy Practitioners (JCPP).  As a JCPP member, AMCP ... period to develop a scalable, viable and consistent ... "Pharmacists are fast becoming one of the most ...
Breaking Medicine Technology:Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2
... Reportlinker.com announces that a new market ... Commercial Insight: Antihormonal Cancer ... generic sales erosion ... therapies are a class of drugs used ...
... NEW YORK, Nov. 8, 2010 Reportlinker.com ... is available in its catalogue: ... for optimizing growth in key regions and ... The flurry of recent ...
Cached Medicine Technology:Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 2Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 3Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 4Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 5Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 6Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 7Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 8Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 9Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 2Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 3Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 4Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 5Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 6Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 7
(Date:7/31/2014)... CITY, Mo. (PRWEB) July 31, 2014 ... of highly experienced, sub-specialty trained neurosurgeons at the ... of the Spine Program and director of spine surgery. ... in Richland, Wash. , “Dr. Upadhyaya has been recognized ... invasive and complex spine issues. His addition to the ...
(Date:7/31/2014)... Recognizing that today’s medical students are tomorrow’s ... announced today its student discount program. ... a healthcare-related field, as well as medical residents in ... the conference, scheduled for September 17-20, 2014 in San ... , “As a future Registered Dietitian, I’m excited ...
(Date:7/31/2014)... 2014 When it comes to aesthetics ... and improve. As such, Natalie Sharp's Pure Vitality ... for a new, more focused direction and to provide ... patients! , Pure Vitality Rx is Oyster Bay's premier ... wide variety of services primarily dedicated to women. Services ...
(Date:7/31/2014)... (August 1, 2014) While it is known that members ... use alcohol, a new study finds that female enlistees ... than their civilian counterparts. This study was published today ... journal published on behalf of the Inter-University Seminar on ... and Lucky Tedrow studied surveys of nearly 9,000 men ...
(Date:7/31/2014)... July 31, 2014 Sales in the organic ... to 2014, according to radio talk show host Sharon Kleyne, ... rapid growth since 1990. The US economy in the same ... Power of Water radio show, reported this information following a ... a worldwide manufacturer of organic and natural food products. ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 2Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 3Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 4Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 3Health News:Natalie Sharp's Pure Vitality Rx Upgrade - Partnership With Shangri-La Spa and Website Facelift! 2Health News:Women in military less likely to drink than civilian women 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3
... Synovics,Pharmaceuticals, Inc. (OTC Bulletin Board: SYVC), a ... Gange, has been,appointed Principal Executive Officer of ... responsibility of overseeing all executive functions. Mr. ... of directors and is the Chief,Financial Officer ...
... Nationwide,Health Properties, Inc. (NYSE: NHP ) today ... President, Tax. Mr. Laty had previously been the,Vice President, ... had,over eight years experience with a "Big 4" accounting ... Estate Investment Trusts. Mr. Laty is,a graduate of California ...
... do find 11 anti-seizure drugs heighten suicide risk, and ... 10 (HealthDay News) -- Anti-seizure drugs can cause ... warrant the government,s strongest warning label on them, a ... 20-member panel voted unanimously, with one abstention, to back ...
... of Mental Health estimates that in any given year, ... from some form of anxiety disorder, including debilitating conditions ... (PTSD). It is estimated that nearly 15 percent ... PTSD, underscoring the urgency to develop better treatment strategies ...
... trials, design may also mask risk of HIV drug resistance ... study questions whether vaginal microbicides being developed to help protect ... from the virus that causes AIDS. , The study, ... of the National Academy of Sciences , also shows that, ...
... anti-seizure drugs that showed double the risk , , THURSDAY, ... cause increased suicidal tendencies in patients, a U.S. health ... experts voted unanimously to back the findings on 11 ... Administration, the Associated Press reported. , In ...
Cached Medicine News:Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 2Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 3Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 4Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 5Health News:FDA Advisers Don't Back Epilepsy Drug Warnings 2Health News:Rutgers research identifies brain cells related to fear 2Health News:Rutgers research identifies brain cells related to fear 3Health News:Vaginal Microbicides Might Help More Men Than Women 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 3
... As a prophylaxis for deep vein ... effective combination of graduated sequential compression and ... thrombus formation by increasing venous ejection while ... VenaFlow System includes a pump with tube ...
... Full Transportability: Innovative design allows the ... in for therapy or when to ... Choose the prophylactic method to deliver ... both simultaneously. ,Automatic Garment Detection: Automatically ...
... boot specially lasted for fiberglass casts... ... sole for easy ambulation! ,The SlimLine ... last so it fits better than ... with our stretchable upper, a custom ...
The Low Profile boot provides a durable canvas upper, with an open toe and heel. Padded EVA insole protection. The lower outsole compensates for casting thickness. Available in six unisex sizes....
Medicine Products: